Intravenous immunoglobulin use in dermatology

European Journal of Dermatology

Volumn 7, Issue 7, 1997, Pages 471-473

  Jullien, Denis ^a,b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Dermatomyositis; Epidermolysis bullosa acquisita; Immunomodulation; Intravenous immunoglobulin

Indexed keywords

IMMUNOGLOBULIN G;

ATOPIC DERMATITIS; AUTOIMMUNITY; DERMATOMYOSITIS; DRUG THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; MUCOCUTANEOUS LYMPH NODE SYNDROME; REVIEW; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0030775960     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Mouthon L, Kaveri SV, Spalter SH, Lacroix-Desmazes S, Lefranc C, Desai R, Kazatchkine MD. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996; 104: 3-9.
2. Furukawa F. Kawasaki disease. European J Dermatology 1995; 5: 549-57.
3. Newburger JW. Treatment of Kawasaki disease. Lancet 1996; 347: 1128.
4. Jayne DR, Lockwood CM. Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol 1993; 336: 469-72.
5. Jayne DR, Lockwood CM. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996; 35: 1150-3.
6. Richter C, Schnabel A, Csernok E, Reinhold-Keller E, Gross WL. Treatment of Wegener's granulomatosis with intravenous immunoglobulin. Adv Exp Med Biol 1993; 336: 487-9.
7. Richter C, Schnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis witfi high-dose intravenous immunoglobulin. Clin Exp Immunol 1995; 101.
8. Bewley AP, Keefe M. Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy. Br J Dermatol 1996; 135: 128-9.
9. Wever S, Zillikens D, Brocker EB. Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy. Br J Dermatol 1996; 135: 862-3.
10. Messer G, Sizmann N, Feucht H, Meurer M. High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris. Br J Dermatol 1995; 133: 1014-6.
11. Beckers RC, Brand A, Vermeer BJ, Boom BW. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol 1995; 133: 289-93.
12. Mohr C, Sunderkotter C, Hildebrand A, Biel K, Rutter A, Rutter GH, Luger TA, Kolde G. Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins. Br J Dermatol 1995; 132: 824-6.
13. Meier F, Sonnichsen K, Schaumburg-Lever G, Dopfer R, Rassner G. Epidermolysis bullosa acquisita: efficacy of nigh-dose intravenous immunoglobulins. J Am Acad Dermatol 1993; 29: 334-7.
14. Humbert P, Derancourt C, Aubin F, Agache P. Effects of intravenous gammaglobulins in pemphigus. J Am Acad Dermatol 1990; 22: 326.
15. Tappeiner G, Steiner A. High-dosaqe intravenous gamma-globulin: therapeutic failure in pemphigus and pemphigoia J Am Acad Dermatol 1989; 20: 684-5.
16. Caldwell JB, Yancey KB, Engler RJ, James WD. Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. J Am Acad Dermatol 1994; 31: 827-8.
17. Kofler H, Wambacher-Gasser B, Topar G, Weinlich G, Schuler G, Hintner H, Romani N, Fritsch P. Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita. J Am Acad Dermatol 1997; 36: 331-5.
18. Godard W, Roujeau JC, Guillot B, André C, Rifle G. Bullous pemphigoid and intravenous gammaglobulin. Ann Intern Med 1985; 103: 965.
19. Adoue D, Vilain C, Fontan B, Le Tallec Y, Albared JL, Oksman F. Utilisation de très faibles doses d'immunoglobulines intraveineuses pour le traitement des pemphigoïdes bulleuses. Press Med 1987; 16: 1625-7.
20. Roujeau JC, Revuz J. Les immunoglobulines intraveineuses ont-elle une place dans le traitement de la pemphigoïde bulleuse? Press Med 1988; 17: 168.
21. Vedanarayanan V, Subramony SH, Ray LI, Evans OB. Treatment of childhood dermatomyositis with high dose intravenous immunoglobulin. Pediatr Neurol 1995; 13: 336-9.
22. Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991; 91: 169-72.
23. Galeazzi M, Bellucci AM, Girardelli CR, Bono R, De Pita O, Puddu P. Efficacy of intravenous immunoglobulin therapy in a case of juvenile dermatomyositis. Clin Rheumatol 1996; 15: 215-6.
24. Collet E, Dalac S, Maerens B, Courtois JM, Izac M, Lambert D. Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br J Dermatol 1994; 130: 231-4.
25. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000.
26. Dalakas MC. Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease. J Clin Immunol 1995; 15: 70S-5S.
27. Breems DA de Haas PW, Visscher F, Sabbe U, Busch HF, van Doom PA. Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis. Ned Tijdschr Geneeskd 1993; 137: 1979-82.
28. Cherin P, Piette JC, Wechsler B, Bletry O, Ziza JM, Laraki R, Godeau P, Herson S. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol 1994; 21: 1092-7.
29. Dalakas DC. Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies. Clin Exp Immunol 1996; 104: 55-60.
30. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94: 1729-35.
31. Shoenfeld Y, Krause I, Blank M. New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation. Ann Rheum Dis 1997; 56: 5-11.
32. Schroeder JO, Zeuner RA, Euler HH, Loffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 1996; 23: 71-5.
33. Francloni C, Galeazzi M, Fioravanti A, Gelli R, Megale F, Marcolongo R. Long-term i.v. 1g treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12: 163-8.
34. Barron KS, Sher MR, Silvermann ED. Intravenous immunoglobulin therapy: magic of black magic. J Rheumatol Suppl 1992; 33: 94-7.
35. Hashkes PJ, Lovell DJ. Vasculitis in systemic lupus erythematosus following intravenous immunoglobulin therapy. Clin Exp Rheumatol 1996; 14: 673-5.
36. Silvestris F, D'Amore O, Cafforio P, Savino L, Dammacco F. Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti-DNA-reactive IgG. Clin Exp Immunol 1996; 104: 91-7.
37. Kimata H. High dose gammaglobulin treatment for atopic dermatitis. Arch Dis Child 1994; 70: 335-6.
38. Gelfand EW, Landwehr LP, Esterl B, Mazer B. Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Clin Exp Immunol 1996; 104: 61-6.
39. Sanwo M, Nwadiuko R, Beall G. Use of intravenous immunoglobulin in the treatment of severe cutaneous drug reactions in patients with AIDS. J Allergy Clin Immunol 1996; 98: 1112-5.
40. Amato GM, Travia A, Ziino O. The use of intravenous high-dose immunoglobulins (IGIV) in a case of Stevens-Johnson syndrome. Pediatr Med Chir 1992; 14: 555-6.
41. Mian EU, Gianfaldoni R, Mian M. The use of intravenous immunoglobulins in patients with severe burns. Clin Ter 1992; 141: 75-81.
42. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 1994; 97: 79-83.